检索结果-南通市图书馆

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese Journal of Cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis group Evidence-based Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Hospital Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Division of Therapeutic Drug Monitoring of chinese Pharmacological society(CPS) Expert Committee on Lymphoma of chinese society of Clinical Oncology(CSCO) Expert Committee on Leukemia of chinese society of Clinical Oncology(CSCO) society of Integrative Cardio-Oncology of China Anti-Cancer association(CACA) chinese society of Hematology of chinese medical association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

2023 chinese national clinical practice guideline on diagnosis and management of ulcerative colitis

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第14期137卷 1642-1646页

作者： Inflammatory Bowel Disease group, chinese society of Gastroenterology, chinese medical association Inflammatory Bowel Disease Quality Control Center of China Inflammatory Bowel Disease group Chinese Society of Gastroenterology Chinese Medical Association Inflammatory Bowel Disease Quality Control Center of China

The role of chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease (IBD) is self-evident. As clinical and basic research in China becomes standardized under a better understanding of IBD, more data on chinese patients have become available to develop a consensus and guideline. This guideline, collaboratively developed by the IBD group, chinese society of Gastroenterology, incorporates the latest international consensus statements, domestic research findings, and practical considerations, as an update based on the 2018 chinese consensus on IBD management. The IBD guideline consists of two parts: ulcerative colitis (UC) and Crohn's disease, and this manuscript presented the UC part. The evidence used in this guideline was collected and analyzed by the standard of guideline, and the contents were organized as problem statements, for clarity. The formulation of this guideline aimed to reflect the latest progress in IBD, providing comprehensive and valuable guidance for the clinical management of IBD.

关键词：

同方期刊数据库

chinese national clinical practice guidelines on the prevention,diagnosis,and treatment of early gastric cancer

在线全文

学校读者我要写书评

暂无评论

chinese medical Journal 2024年第8期137卷 887-908页

作者： Peng Li Ziyu Li Enqiang Linghu Jiafu Ji society of Digestive Endoscopy of the chinese medical association Colorectal Surgery group of the chinese medical association chinese association of Gastroenterologists&Hepatologists National Clinical Research Center for Digestive Diseases chinese medical Journal Clinical Practice Guideline Collaborative Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China Department of Gastrointestinal Surgery Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Gastroenterology and Hepatology the First Medical CenterChinese People’s Liberation Army General HospitalBeijing 100853China 不详

Background:Gastric cancer is one of the most common malignant tumors in the digestive system in *** comprehensive practice guidelines for early gastric cancer in China are currently ***,we created the chinese national clinical practice guideline for the prevention,diagnosis,and treatment of early gastric ***:This clinical practice guideline(CPG)was developed in accordance with the World Health Organization’s recommended process and with the Grading of Recommendations Assessment,Development,and Evaluation(GRADE)in assessing evidence *** used the Evidence to Decision framework to formulate clinical recommendations to minimize bias and increase transparency in the CPG development *** used the Reporting Items for practice Guidelines in HealThcare(RIGHT)statement and the Appraisal of Guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guidelines to ensure completeness and transparency of the ***:This CPG contains 40 recommendations regarding the prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer based on available clinical studies and *** provide recommendations for the timing of Helicobacter pylori eradication,screening populations for early gastric cancer,indications for endoscopic resection and surgical gastrectomy,follow-up interval after treatment,and other ***:This CPG can lead to optimum care for patients and populations by providing up-to-date medical *** intend this CPG for widespread adoption to increase the standard of prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer;thereby,contributing to improving national health care and patient quality of life.

关键词： Early gastric cancer Prevention Screening Diagnosis Treatment Follow-up

Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children

在线全文

学校读者我要写书评

暂无评论

Infectious Diseases & Immunity 2024年第3期4卷 106-120页

作者： chinese society of Infectious Diseases chinese medical association chinese society of Hepatology chinese medical association group of Infectious Diseases chinese pediatric society chinese medical association National Clinical Research Center for Infectious Diseases(Beijing) Fu-Sheng Wang Shishu Zhu Min Zhang Jianshe Wang Shuangjie Li Junliang Fu Yuanyuan Li Yuming Guo Jing Li Hongmei Xu Wenxian Ouyang Yuemin Nan Sainan Shu Shuangsuo Dang Xiaoyuan Xu Taisheng Li Jinlin Hou 不详 The Fifth medical Center of PLA General Hospital Beijing 100039China Fudan University Children’s Hospital Hunan Children’s Hospital Children’s Hospital of Chongqing medical University Third Hospital Hebei Medical University Tongji Hospital Tongji Medical CollegeHuazhong University of Science and Technology The Second Affiliated Hospital of Xi’an Jiaotong University Peking University First Hospital Peking Union medical College Hospital Chinese Academy of Medical Sciences&Peking Union Medical College Nanfang Hospital Southern Medical University

The aim of this consensus is to standardize the prevention, diagnosis, and treatment of chronic hepatitis B in children and to achieve the goal of “eliminating viral hepatitis as a major public health threat by 2030” issued by the World Health Organization. Formulated by organized experts of the chinese society of Infectious Diseases and chinese society of Hepatology, chinese medical association;group of Infectious Diseases, chinese pediatric society, chinese medical association;and the National Clinical Research Center for Infectious Diseases (Beijing), the consensus provides the latest evidence and recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B in children.

关键词： Chronic hepatitis B Children Treatment Prevention Consensus

chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations(2023 edition)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese medical Journal 2024年第9期137卷 1016-1018页

作者： The society of Cancer Precision Medicine of chinese Anti-Cancer association The Lung Cancer Expert group of chinese medical association Publishing House Baohui Han Hua Zhong 不详 Department of Respiratory Medicine Shanghai Chest HospitalSchool of MedicineShanghai JiaoTong UniversityShanghai 20030China Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine

Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed“forbidden territory”for immunotherapy.[1]With the continuous generation of evidence,immunotherapy is expected to bring hope for such NSCLC with oncogenic driver mutations after acquired tyrosine kinase inhibitor(TKI)***,given the intricate interplay between driven mutations,targeted therapy,and immune microenvironment,the efcacy of immunotherapy in advanced NSCLC patients with diverse oncogenic driver mutations remains a topic of ongoing *** this context,chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Oncogenic Driver Mutations(2022 edition)wasrst launched in 2022 by the society of Cancer Precision Medicine of chinese Anti-Cancer association and the Lung Cancer Expert group of chinese medical Journals,aiming to provide standardized treatment guidance for clinical practice.

关键词： immunotherapy cancer lung

chinese national clinical practice guidelines on prevention,diagnosis and treatment of early colorectal cancer

在线全文

学校读者我要写书评

暂无评论

chinese medical Journal 2024年第17期137卷 2017-2039页

作者： Jingnan Li Hongwei Yao Yun Lu Shutian Zhang Zhongtao Zhang society of Digestive Endoscopy of the chinese medical association Colorectal Surgery group of the chinese medical association chinese association of Gastroenterologist&Hepatologist National Clinical Research Center for Digestive Diseases chinese medical Journal Clinical Practie Guideline Collaborative Department of Gastroenterology Peking Union Medical College HospitalChinese Academy of Medical SciencesPeking Union Medical CollegeBeijing 100730China Department of General Surgery Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseasesBeijing 100050China Department of General Surgery The Affiliated Hospital of Qingdao UniversityQingdaoShandong 266555China Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China 不详

Background:The incidence and mortality of colorectal cancer(CRC)in China are increasing in recent *** clarified pathogenesis and detectable precancerous lesions of CRC make it possible to prevent,screen,and diagnose CRC at an early *** the development of endoscopic and surgical techniques,the choice of treatment for early CRC is also worth further discussion,and accordingly,a standard follow-up program after treatment needs to be ***:This clinical practice guideline(CPG)was developed following the recommended process of the World Health Organization,adopting Grading of Recommendations Assessment,Development and Evaluation(GRADE)in assessing evidence quality,and using the Evidence to Decision framework to formulate clinical recommendations,thereby minimizing bias and increasing transparency of the CPG development *** used the Reporting Items for practice Guidelines in HealThcare(RIGHT)statement and Appraisal of Guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guides to ensure the guideline’s completeness and ***:This CPG comprises 46 recommendations concerning prevention,screening,diagnosis,treatment,and surveillance of *** these recommendations,we have indicated protective and risk factors for CRC and made recommendations for *** proposed a suitable screening program for CRC based on the chinese *** also provided normative statements for the diagnosis,treatment,and surveillance of CRC based on existing clinical evidence and ***:The 46 recommendations in this CPG are formed with consideration for stakeholders’values and preferences,feasibility,and *** are generalizable to resource-limited settings with similar CRC epidemiology pattern as China.

关键词： Colorectal cancer Early detection of cancer Prevention Screening Diagnosis Treatment Follow-up Guideline

Stress Echocardiography for Chronic Coronary Syndrome:Clinical Practice Guidelines(2023)

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第5期21卷 475-505页

作者： Peng-Fei ZHANG Jia-Wei TIAN Tian-Gang ZHU Jue-Fei WU Xiao-Ping LENG Yi WANG Meng-Meng LI Xin-Hao LI Qian-Qian WANG Xiao-Peng FENG Jia-Yan LV Li-Xue YIN Yun ZHANG Mei ZHANG chinese society of Echocardiography,Superficial Tissue and Vascular group of chinese society of Ultrasound in Medicine,Ultrasound Professional Committee of chinese Medicine Education association State Key Laboratory for Innovation and Transformation of Luobing Theory Key Laboratory of Cardiovascular Remodeling and Function ResearchChinese Ministry of EducationChinese National Health Commission and Chinese Academy of Medical SciencesDepartment of CardiologyQilu Hospital of Shandong UniversityJinanChina The Second Affiliated Hospital of Harbin medical University HaerbinChina Peking University People's Hospital BeijingChina Sichuan Province People's Hospital ChengduChina Nanfang Hospital Southern Medical UniversityGuangzhouChina Peking Union medical College Hospital Chinese Academy of Medical SciencesBeijingChina 不详

In the context of the People's Republic of China,coronary artery disease(CAD)presents a sig-nificant clinical challenge,with over 11.3 mil-lion patients ***,the diagnos-is of CAD has predominantly relied on invasive coronary angiography.[1]However,recent advances in clinical research have revealed a notable trend:a substantial 82% of patients subjected to such invas-ive diagnostics do not necessitate interventional therapy.

关键词： coronary clinical patients

Clinical Management Guidelines for Intrahepatic Cholestasis of Pregnancy

在线全文

学校读者我要写书评

暂无评论

Maternal-Fetal Medicine 2024年第1期6卷 13-22页

作者： Obstetrics group of the Gynecology and Obstetrics Branch of chinese medical association Perinatal Medicine Branch of chinese medical association Xinyang Yu Huixia Yang Hongbo Qi 不详 medical University Chongqing 400016China Department of Obstetrics and Gynecology Peking University First HospitalBeijing 100034China Department of Obstetrics and Gynecology Women and Children's Hospital of Chongqing Medical UniversityChongqing 401147China

Intrahepatic cholestasis of pregnancy(ICP)is a significant gestational complication in late pregnancy,potentially leading to severe perinatal complications such as intrauterine fetal demise and preterm *** Obstetrics group of the Gynecology and Obstetrics Branch and the Perinatal Medicine Branch of the chinese medical association organized a panel of domestic experts to deliberate and propose recommendations based on domestic and international guidelines,recent evidence-based medical evidence about key clinical issues including risk factors,clinical manifestations,perinatal outcomes,diagnosis,severity grading,maternal and fetal monitoring,treatment methods,timing,and methods of pregnancy termination,and postpartum follow-up for ICP,with the aim to guide its clinical diagnosis,treatment,and management.

关键词： Cholestasis,Intrahepatic Bile Acids Stillbirth Preterm Birth Diagnostic and Therapeutic Guidelines(Theme)

chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第19期137卷 2272-2293页

作者： Wang Xu’an Bai Yongrui Chai Ningli Li Yexiong Linghu Enqiang Wang Liwei Liu Yingbin society of Hepato-pancreatobiliary Surgery of chinese Research Hospital association society of Digestive Endoscopy of the chinese medical association chinese medical Journal Clinical Practice Guideline Collaborative Department of Biliary and Pancreatic Surgery Renji Hospital Shanghai Jiao Tong University School of Medicine State Key Laboratory of Systems Medicine for Cancers Shanghai Cancer Institute Shanghai Key Laboratory for Cancer Systems Regulation and Clinical Translation Shanghai China Department of Radiation Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China Department of Gastroenterology and Hepatology the First Medical Center Chinese People’s Liberation Army General Hospital Beijing China State Key Laboratory of Molecular Oncology and Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Beijing China State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Department of Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China

Background: Biliary tract carcinoma (BTC) is relatively rare and comprises a spectrum of invasive tumors arising from the biliary tree. The prognosis is extremely poor. The incidence of BTC is relatively high in Asian countries, and a high number of cases are diagnosed annually in China owing to the large population. Therefore, it is necessary to clarify the epidemiology and high-risk factors for BTC in China. The signs associated with BTC are complex, often require collaborative treatment from surgeons, endoscopists, oncologists, and radiation therapists. Thus, it is necessary to develop a comprehensive chinese guideline for ***: This clinical practice guideline (CPG) was developed following the process recommended by the World Health Organization. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess the certainty of evidence and make recommendations. The full CPG report was reviewed by external guideline methodologists and clinicians with no direct involvement in the development of this CPG. Two guideline reporting checklists have been adhered to: Appraisal of Guidelines for Research and Evaluation (AGREE) and Reporting Items for practice Guidelines in Healthcare (RIGHT).Results: The guideline development group, which comprised 85 multidisciplinary clinical experts across China. After a controversies conference, 17 clinical questions concerning the prevention, diagnosis, and treatment of BTC were proposed. Additionally, detailed descriptions of the surgical principles, perioperative management, chemotherapy, immunotherapy, targeted therapy, radiotherapy, and endoscopic management were ***: The guideline development group created a comprehensive chinese guideline for the diagnosis and treatment of BTC, covering various aspects of epidemiology, diagnosis, and treatment. The 17 clinical questions have important reference value for the management of BTC.

关键词： Biliary tract carcinoma Etiology Diagnosis Treatment Surgery